



Day 1, Wednesday 27 November 2019				
Parallel Session 1: Emerging and vector-borne diseases: surveillance approaches	Parallel Session 2: Vaccine-preventable diseases : vaccine coverage, safety and uptake	Parallel Session 3: Healthcare-associated infections: burden and prevention		
Time: 11:00-12:40	Time: 11:00-12:40	Time: 11:00-12:40		
Moderator:	Moderator:	Moderator:		
 Using epidemiological information to map outbreak networks and inform public health action during the 2018/19 Ebola outbreak in the Democratic Republic of the Congo (DRC), Rebecca Hams Strengthening preparedness for West Nile Virus in Europe following the 2018 transmission season: an ECDC protocol to conduct After Action Reviews, Flavia Riccardo Automatic information extraction and relevance evaluation of epidemiological texts using natural language processing, Auss Abbood The role of Epidemic Intelligence in Portugal: Analysis of the reported events in the National Weekly Threats Bulletin, Report on Observations, News, Data and Alerts (RONDA), Vasco Ricoca Peixoto 	 2.1. "When you welcome well, you vaccinate well": Reasons for suboptimal vaccination coverage in urban settings in Conakry, Republic of Guinea, Julita Gil Cuesta 2.2. Risk of Guillain-Barré Syndrome after vaccination against human papillomavirus (HPV): a systematic review, Tamara Sonia Boender 2.3. Underreporting of the 5-year tetanus, diphtheria, pertussis and polio booster vaccination in the Danish Vaccination Register, Ida Glode Helmuth 2.4. Uptake of the second measles-mumps-rubella vaccination by school in Denmark, Palle Valentiner-Branth 	 3.1. A genomic profile of Mycobacterium abscessus isolates from Cystic Fibrosis patients in Scotland, Elizabeth Dickson 3.2. Long-term excess mortality after Clostridium difficile infection by place of origin; a nationwide study from Denmark, 2010-18, Sophie Gubbels 3.3. Healthcare associated infection in home healthcare; what, why and how?, Ana Hoxha 3.4. Incidence of hospital-acquired Clostridium difficile infection and association with antimicrobial consumption in Ireland, 2013-2017, Annalisa Quattrocchi 3.5. Alerting all neighhours:, Aimée Tjon-A-Tsien 		
Parallel Session 4: Antimicrobial resistance and Healthcare-associated infections (Epidemiology)	Parallel Session 5: Emerging and vector-borne diseases: epidemiology	Parallel Session 6: Food- and waterborne diseases and zoonoses outbreaks (1)		
Time: 14:30-15:30	Time: 14:30-15:30	Time: 14:30-15:30		
Moderator:	Moderator:	Moderator:		
 4.1. Descriptive epidemiology of carbapenemase-producing enterobacteriaceae in Northern Ireland, 2012 to 2017, Joseph Pett 4.2. Defining nosocomial E. coli transmission using an integrated genomic and epidemiological approach, Catherine Ludden 4.3. Molecular epidemiology of community- and healthcare associated Clostridium difficile infections in Jönköping, Sweden, October 2017 – March 2018, Theresa Enkirch 	 5.1. High subsequent mortality of Ebola virus disease survivors in Guinea: a nationwide retrospective cohort study, Lorenzo Subissi 5.2. Cross-Protection of Dengue Virus Infection against Congenital Zika Syndrome, Northeastern Brazil, Carlo Fischer 5.3. Surveillance of hospitalisations during a large outbreak shows severe dengue remains stable, La Réunion, 2018-2019, Eve Robinson 	 6.1. Outbreak of Gastrointestinal Anthrax Following Consumption of Diseased Goats in Hawi Gudina District, Oromia Region, Ethiopia, 2017, Belay Mamuye 6.2. E. coli O157 and leafy green outbreaks in Canada, 2015- 2019, Jennifer Cutler 6.3. Investigating salmonella contamination in frozen feeder mice being supplied to the UK market, Matt Edmunds 		



Day 2: Thursday, 28 November 2019			
Parallel Session 7: Food- and waterborne diseases and zoonoses: Public Health Microbiology and Surveillance Methods	surveillance (1)	Parallel Session 9: Influenza: Vaccination and intervention (1) Time: 11:00-12:40	
Time: 11:00-12:40	Time: 11:00-12:40	Moderator:	
Moderator:	Moderator:		
 7.1. Interactive application to explore time series of European infectious disease surveillance data for signal detection: the ECDC EpiSignalDetection R-package, Lore Merdrignac 7.2. Evaluation of Salmonella surveillance questionnaire response combined with SMS messaging in Greater Manchester, United Kingdom, Alex Bhattacharya 7.3. Evaluation of national legionellosis surveillance in Norway, 2008 to 2017, Cecilia Wolff 7.4. Genomic Comparisons to Investigate Virulence Differences Between Australian and International Strains of O157 Shiga Toxin-Producing Escherichia coli, Alexander Pintara 7.5. Benefits of Sentinel Laboratory Surveillance of Human Campylobacter Infections in Ireland, 2019, Carina Brehony 	 8.1. Vaccination with the 13-valent pneumococcal conjugate vaccine in an outbreak of Streptococcus pneumoniae serotype 4 in a Norwegian shipyard, Anneke Steens 8.2. Impact of vaccination programmes with 10 and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease incidence by age group in SpIDnet/I-MOVE+ countries, Camelia Savulescu 8.3. The changing face of diphtheria 70 years since vaccine introduction in the United Kingdom, Charlotte Gower 8.4. Effectiveness of 10- and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in children <5 years: lessons learnt from SpIDnet multicentre study, Camelia Savulescu 	 9.1. Vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2): Results from the 2018/19 European I-MOVE primary care multicentre study, Esther Kissling 9.2. 2018/19 primary care influenza vaccine effectiveness against influenza A(H3N2) in Europe: no effectiveness among 15–64 year olds, Esther Kissling 9.3. Vaccine effectiveness against influenza A(H3N2) and A(H1N1) in older adults and the effects of age-group and statins: Results from the I-MOVE hospital network, 2018–19, Angela Rose 9.4. Low frequency of reduced neuraminidase inhibitor susceptibility in twelve EU/EEA countries, 2008-2018, Eeva Broberg 	
Parallel Session 10: Antimicrobial resistance and Healthcare-associated infections (Surveillance)	Parallel Session 11: Late breakers	Parallel Session 12: Influenza: Vaccination and intervention (2)	
Time: 14:30-15:30	Time: 14:30-15:30	Time: 14:30-15:30	
Moderator:	Moderator:	Moderator:	
iviouel atol .		INIOGEI ATOL.	
 10.1. External quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in primary laboratories in Germany, Regina Selb 10.2 Use of the automated Danish Clostridium difficile surveillance system for reporting to the manual European surveillance system, Manon Chaine 10.3 Hospital outbreaks of group B streptococcal (GBS) infection: a systematic review, Simon Collin 	11.1.	 12.1. Impact of national influenza vaccination strategy among the high-risk Portuguese population in severe influenza outcomes, Ausenda Machado 12.2. Deaths, hospitalisations and GP visits attributable to influenza infection averted by the influenza vaccination programme in the Netherlands among persons aged 65 and older, seasons 2015/16–2017/18, Frederika Dijkstra 12.3. Seasonal influenza vaccine effectiveness for the prevention of laboratory-confirmed influenza in asthma during the influenza seasons 2010-16 in Scotland: a test-negative design case-control study, Eleftheria Vasileiou 	
Parallel Session 13: HIV and STI: prevalence and prevention	Parallel Session 14: Respiratory disease: surveillance and modelling	Parallel Session 15: Vaccine-preventable diseases surveillance (2)	
Time: 17:00-18:40	Time: 17:00-18:40	Time: 17:00-18:40	
Moderator:	Moderator:	Moderator:	
 13.1. Prevalence of gonorrhea and chlamydia in a community clinic for Men who Have Sex with Men in Portugal, Sofia Ribeiro 13.2. Does using pre-exposure prophylaxis for HIV increase the risk of acquiring other sexually transmitted infections?, Laia Fina Homar 13.3. Estimating the infection time among people who inject drugs during an HIV-outbreak in Athens, Greece: Evidence that interventions significantly decreased the number of new transmissions, Evangelia-Georgia Kostaki 13.4. What is the optimal testing strategy for oropharyngeal Neisseria gonorrhoeae in women visiting STI clinics?, Geneviève van Liere 13.5. HIV in women in the EU/EEA: 25 years of surveillance data to inform prevention and control, Anastasia Pharris 	 14.1. Non-influenza viruses associated with Severe Acute Respiratory Infections during influenza seasons 2015/2016 to 2017/2018, Belgium, Lorenzo Subissi 14.2. Surveillance of enterovirus types causing infection in Wales from 2015 to 2019, Simon Cottrell 14.3. Identification of infection sources of Legionella using WGS, 2016-2018, Austria, Ali Chakeri 14.4. Presentation and healthcare delays among people with tuberculosis in London, and the impact on treatment outcome, Poppy Evenden 	 15.1. Invasive Group B Streptococcus infections in adults in England, 2015-2016: analysis of population surveillance data, Simon Collin 15.2. Clustering of susceptibility to measles in households: perspective for the next two decades, Elise Kuylen 15.3. National burden of measles complications in Italy during a large outbreak in 2017-2018, Adriano Grossi 15.4. Measles in the EU/EEA in 2016-2019: where are cases imported from?, Benedetto Simone 	



Day 3: Friday, 29 November 2019				
Parallel Session 16: Vaccine-preventable diseases: Epidemiology		Parallel Session 18: Food- and waterborne diseases and zoonoses outbreaks (2)		
Time: 11:00-12:40	Time: 11:00-12:40	Time: 11:00-12:40		
Moderator:	Moderator:	Moderator:		
 16.1. Rubella Outbreak Investigation in Kuyu District North Shoa Zone, Oromia Region, Ethiopia, 2018: Community Based Case Control Study, Abdulbari Abdulkadir 16.2.Lessons learned from the transmission chain of a measles outbreak in Stockholm County 2017, Joanna Nederby Öhd 16.3.Age group-specific Rotavirus Infection and Acute Gastroenteritis five years after the introduction of rotavirus immunisation in the UK, Charlotte M. Gower 16.4.Increased risk of varicella among pregnant immigrant women from temperate and tropical countries after arrival in Quebec, Canada, Elisa Llorente Pastor 16.5.3 years since the withdrawal of type 2 oral poliovirus vaccine: An update of global epidemiology, Grace Macklin 	for hepatitis C prevalence surveys in the general population (2016-2019), Stine Nielsen 17.3. More than 1,000 people infected by hepatitis C virus through blood transfusions before screening was implemented remain alive but undiagnosed: a nation-wide, retrospective cohort study, Sweden, Viktor Dahl 17.4. Are men who have sex with men (MSM) in Europe	 18.1. Outbreak of Salmonella Agbeni with severe clinical presentation linked to exotic dried fruit mix, Norway, 2019, Tone B Johansen 18.2. Large waterborne gastroenteritis outbreak of mixed origin in Western Macedonia, Greece, January – February 2019, Myrsini Tzani 18.3. An outbreak of Salmonella monophasic Typhimurium associated with several pork products, Denmark, 2018-19, Ida Glode Helmuth 18.4. Consumption of black sausage is associated with a large listeriosis outbreak in Germany, 2018-2019, Amrei Krings 18.5. A whole genome sequencing defined national outbreak of Salmonella Enteritidis associated with the consumption of a raw liquid egg white product, Lara Utsi 		
Parallel Session 19: Vaccine-preventable diseases surveillance (3) Time: 14:30-15:30 Moderator:	zoonoses surveillance Time: 14:30-15:30	Parallel Session 21: Late breakers Time: 14:30-15:30 Moderator:		
 19.1. Anti-PT IgA and anti-ACT IgG are valuable tools for the serodiagnosis of Bordetella pertussis infection in recently vaccinated subjects, Lorenzo Subissi 19.2. Incidence and severity of pertussis hospitalisations in infants aged less than one year, results of PERTINENT sentinel system, 2016-2018, Lore Merdrignac 19.3. Effectiveness of pertussis vaccination during pregnancy against laboratory confirmed pertussis in hospitalised infants aged <61 days in four European countries, PERTINENT, December 2015-December 2018, Lore Merdrignac 	 20.1. Prevalence and correlates of Q fever among abattoir workers in central South Africa: a serological study, Liesl De Boni 20.2. Hepatitis A seroprevalence estimates in Belgium, Ana Hoxha 20.3. Effects of changes in diagnostics and notification criteria on Shiga toxin-producing Escherichia coli surveillance in the Netherlands, 1999-2018, Ingrid Friesema 	21.1.		

